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SObjective: Esophageal adenocarcinoma is thought to arise from lesions produced by chronic esophageal inflam-
mation. Secretory phospholipase A2 is an important mediator of mucosal response to gastroesophageal reflux, but
its role in the function of mature cancer cells is unclear. We sought to determine the influence of group IIa secre-
tory phospholipase A2 on proliferation of human esophageal adenocarcinoma cells.
Methods: FLO-1 and OE33 cells derived from human esophageal adenocarcinoma were cultured with standard
techniques. Cells were treated with 1-, 5-, 10-, and 20-mmol/L doses of 5-(4-benzyloxyphenyl)-4S-(7-phenylhep-
tanoylamino)pentanoic acid, a specific inhibitor of group IIa secretory phospholipase A2, for 72 hours. Gene for
group IIa secretory phospholipase A2 (PLA2G2A) was overexpressed and silenced with lentiviral infection tech-
niques. Cell proliferation and viability were measured with standard 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide and bromodeoxyuridine incorporation assays. All assays were performed in triplicate.
PLA2G2A expression was measured with quantitative reverse transcriptase polymerase chain reaction; protein
levels were detected with immunofluorescence microscopy. Statistical analysis was by analysis of variance
with Fisher post hoc analysis.
Results: Secretory phospholipase A2 protein was found in both malignant esophageal adenocarcinoma cell lines.
Treatment with specific group IIa secretory phospholipase A2 inhibitor resulted in dose-dependent reductions in
growth and cell number in both cell lines. Overexpression of PLA2G2A resulted in enhanced cancer cell growth,
whereas gene knockdown attenuated growth.
Conclusions: Group IIa secretory phospholipase A2 appears significant in growth and proliferation of human
esophageal adenocarcinoma cells. Secretory phospholipase A2 inhibition should be studied further regarding
potential chemopreventive and therapeutic properties in esophageal adenocarcinoma. (J Thorac Cardiovasc
Surg 2010;139:591-9)Esophageal adenocarcinoma of the gastroesophageal junc-
tion is currently the cancer with the fastest increasing
incidence in the United States.1 Since 1970, its incidence
in some populations has increased more than 800%.1 The
development of esophageal cancer is thought to be a multi-
step process involving the accumulation of genetic events
that result in abnormalities of cell cycle regulation. This re-
sults in formation of preneoplastic and eventually malignant
lesions in the esophageal mucosa.2 The central factor in the
development of these genetic events and malignant lesions is
inflammation related to gastroesophageal reflux disease.3
Reflux disease is the most significant risk factor for the
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The Journal of Thoracic and Cawith long-standing reflux disease are 43 times more likely
to have adenocarcinoma of the esophagus develop.2
Several molecular factors are thought to mediate the gen-
eration of mucosal inflammation in reflux disease and aid in
the development of malignancy. Such factors include cyclo-
oxygenase-2 (COX-2), tumor necrosis factor a, and induc-
ible nitric oxide synthase.4,5 Recently, we confirmed the
enzyme secretory phospholipase A2 (sPLA2) as another im-
portant mediator of esophageal mucosal inflammation.6 The
enzymatic activity of phospholipase enzymes results in the
generation of bioactive molecules such as lysophospholi-
pids, prostaglandins, leukotrienes, and free fatty acids. In
particular, sPLA2 has been implicated as a pathogenic factor
in a variety of inflammatory diseases, including acute pan-
creatitis, septic shock, adult respiratory distress syndrome,
Crohn disease, ulcerative colitis, bronchial asthma, and al-
lergic rhinitis.7
The role of sPLA2 in the function of the cancer cell is not
clear. Upregulation of sPLA2 has been described in several
human cancers, including prostate, ovarian, and intestinal
tumors, and apparently its presence has integral effects on
both growth regulation and level of virulence of these can-
cers.7 The findings by others demonstrating that sPLA2
levels are increased in the mucosa of patients with bothrdiovascular Surgery c Volume 139, Number 3 591
Abbreviations and Acronyms
5-LOX ¼ 5-lipoxygenase
BrdU ¼ bromodeoxyuridine
COX-2 ¼ cyclooxygenase-2
FBS, fetal bovine serum
GFP ¼ transgene for green fluorescent protein
LDH ¼ lactate dehydrogenase
LVUT ¼ lentiviral expression vector
pLVUT-tTR-KRAB
MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide
PBS ¼ phosphate-buffered saline solution
PCR ¼ polymerase chain reaction
PGE2 ¼ prostaglandin E2
PLA2G2A ¼ gene for group IIa secretory
phospholipase A2
RT-PCR ¼ reverse transcriptase polymerase
chain reaction
shRNA ¼ short hairpin RNA
sPLA2 ¼ secretory phospholipase A2
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SBarrett esophagus and esophageal carcinoma suggest that it
may play a role in more advanced metaplastic states as well
as in the early inflammatory process in esophageal disease.8
Because of our findings demonstrating the role of sPLA2 in
esophageal mucosal inflammation, we hypothesized that
sPLA2 may influence the growth and proliferation of esoph-
ageal cancer cells.
MATERIALS AND METHODS
Cell Lines and Treatment
The esophageal adenocarcinoma cell line OE33 was purchased from
Sigma (Sigma Chemical Company, St Louis, Mo), and the cell line FLO-1
was a generous gift from Dr David Beer (Department of Surgery, University
of Michigan, Ann Arbor, Mich). OE33 cells were grown in Roswell Park
Memorial Institute 1640 medium supplemented with 10% fetal bovine
serum (FBS) and antibiotics. FLO-1 cells were grown in Dulbecco modified
Eagle minimal essential medium supplemented with 10% FBS and antibi-
otics. HEK293 T cells were obtained from the American Type Culture
Collection (Manassas, Va) and grown in Dulbecco modified Eagle minimal
essential medium supplemented with 10% FBS and antibiotics. All cells
were grown incubated at 37 C in a humidified atmosphere of 95% air
and 5% carbon dioxide. The sPLA2 inhibitor 5-(4-benzyloxyphenyl)-
4S-(7-phenylheptanoylamino)pentanoic acid was purchased from Sigma
and dissolved in dimethyl sulfoxide. Stock solutions of the drugwere diluted
in medium before each experiment such that the concentration of dimethyl
sulfoxide never exceeded 0.1%.
Reverse Transcriptase Polymerase Chain Reaction
OE33 and FLO-1 cells were grown in 6-well plates until confluent. Cells
were then rinsed twice with cold phosphate-buffered saline solution (PBS)
and lysedwith Buffer RLT fromRNeasy kit (Qiagen, Valencia, Calif). RNA
was extracted according to the protocol provided with the kit. Reverse tran-
scription was performed in the usual fashion. Primers used to amplify the
genes for group IIa sPLA2 (PLA2G2A) and glyceraldehyde-3-phosphate592 The Journal of Thoracic and Cardiovascular Surgdehydrogenase (GAPDH) are shown in Table 1. Polymerase chain reaction
(PCR) product bands were quantified from ethidium-stained gels with Na-
tional Institutes of Health ImageJ software (http://rsbweb.nih.gov/ij/).
Quantitative PCR was carried out with the Rotor-Gene 6000 Real-Time
DNA Detection System (Qiagen) with SYBR Green PCR Master Mix (Ap-
plied Biosystems Inc, Foster City, Calif). All reactions were performed in
a total volume of 20 mLwith 20 ng complementary DNA (based on the orig-
inal RNA concentration) and 0.5 mg concentrations of the forward and re-
verse primers. Negative (no added template) controls were run for each
set of experiments. PCR reactions were set at 95C for 5 minutes, followed
by 40 cycles including a denaturation step at 95C for 5 seconds, an anneal-
ing step at 63C for 10 seconds, and an extension step at 72C for 15 sec-
onds. The last step included a slow increase in temperature from 72C to
95C, or melt curve. Verification of the appropriate product was conducted
by melt curve analysis as well as agarose gel electrophoresis. Data were
calculated as relative abundance of heat shock protein 25 gene (HSPB1)
relative to that of the glyceraldehyde-3-phosphate dehydrogenase gene
(GAPDH) with the DDCt method.
Immunofluorescence Microscopy
OE33 and FLO-1 cells were plated on 8-well glass chamber slides at
a density of 53 103 cells/chamber. Cells were incubated in growth medium
for 72 hours before fixation with a mixture of 70% acetone and 30%meth-
anol for 5 minutes, followed by fixation with 4% paraformaldehyde for 10
minutes. Sections were washed with PBS, blocked with 10% normal serum
for 30 minutes, and incubated overnight with 5-mg/mL polyclonal rabbit
anti–human group IIa sPLA2 in PBS containing 1% bovine serum albumin
antibody (Biovendor, Candler, NC). After washing with PBS, sections were
incubated with Cy3-conjugated matched IgG at 1:150 dilution with PBS
containing 1% bovine serum albumin (Jackson Immunoresearch, West
Grove, Pa). To assess specificity, cells in adjacent chambers were incubated
with non–immune-matched IgG (5 mg/mL in PBS containing 1% bovine se-
rum albumin) and otherwise processed identically (negative controls). Pri-
mary incubation was performed at 4C, and all other incubations were
performed at room temperature. Bis-benzimide was used to stain nuclei
(40,6-diamidino-2-phenylindole, imaged on the blue channel) and wheat
germ agglutinin to stain cell membranes (labeled with Alexa 488 and im-
aged on the green channel). Group IIa sPLA2 was imaged on the red
(Cy3) channel. Microscopic observation and photography were performed
with a Leica DMRXA confocal microscope (Leica Mikroskopie und Sys-
teme GmbH, Wetzlar, Germany).Quantitation of Viable Cell Number and Cellular
Proliferation After sPLA2 Inhibition
OE33 and FLO-1 cells were subcultured in 96-well plates at a density of
13 104 cells/well in 10% FBS-containing medium for 48 hours. Cells were
then incubated in reduced serum medium (0.5% FBS) for 24 hours to
induce cell cycle arrest. The medium was then replaced with reduced-serum
medium containing dimethyl sulfoxide (0.1%) or the sPLA2 inhibitor at 1,
5, 10, and 20 mmol/L and incubated for 72 hours. At the end of the treatment,
viable cell numbers were determined with a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay kit (Roche Diagnostics
GmbH, Mannheim, Germany). To verify that any changes in viable cell
number in the treatment groups were not due to cytotoxic effects of the
inhibitory drug, the lactate dehydrogenase (LDH) activities of the cell
supernatants were measured after the 72 hour treatment. LDH is contained
in the cytoplasm of cells and is released into the media of cells undergoing
necrosis.
To confirm that the effects on relative viable cell number were due to ef-
fects on proliferation, cells were treated as described here, and a bromodeox-
yuridine (BrdU) incorporation assay (Roche) was performed according to
manufacturer instructions. This assay quantifies de novo DNA synthesis
as a marker of proliferation.ery c March 2010
TABLE 1. Gene sequences used
Forward Reverse
PLA2G2A RT-PCR primers 50-CCACGGATCGCTGCTGTGTCA 50-TCCTGTTTTGCACAGGTGATT
GAPDH RT-PCR primers 50-GAGTCAACGGATTTGGTGGT 50-GACAAGCTTCCCGTTCTCAG
PLA2G2A full-length
transgene primers
50-GTCGAACCGGTATGAAGACCCTCCTACTGTTG 50-GTCGAGGGCCCTCAGCAACGAGGGGTGCTCCC
PLA2G2A short hairpin
RNA sequences
50-GGCCCATGGGAATTTGGTGAATT
50-GGTGCTAGAAACAAGACGACCTA
50-GGGCTGTGTCACTCATGACTGTT
50-GGGATCAAGTTGACGACAGGAAA
PLA2G2A, Gene for secretory phospholipase A2; RT-PCR, reverse transcriptase polymerase chain reaction; GAPDH, gene for glyceraldehyde-3-phosphate dehydrogenase.
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sPLA2 Gene
The lentiviral expression vector pLVUT-tTR-KRAB (LVUT) was used
for overexpression of the gene for group IIa sPLA2 (PLA2G2A). This vector
contains a transgene coding for green fluorescent protein (GFP) under the
control of the human ubiquitin C RNA polymerase II promoter. The GFP
transgene was removed by restriction digestion with Apa1 and Age1 restric-
tion enzymes (New England Biolabs, Ipswich, Mass) and was replaced with
a transgene coding for PLA2G2A (LVUTPLA2G2A). The PLA2G2A transgeneFIGURE 1. Expression of group IIa secretory phospholipase A2 (sPLA2) protei
copy shows expression of group IIa secretory phospholipase A2 (red) in esophage
cell membranes are stained green. B, Reverse transcriptase polymerase chain reac
esophageal cancer cells. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase;
The Journal of Thoracic and Cawas amplified from complementary DNA of FLO-1 cells by reverse tran-
scriptase PCR (RT-PCR) with specifically designed primers containing
the Age1 restriction sequence on the 50 primer and the Apa1 sequence on
the 30 primer (Table 1). Insertion of the PLA2G2A transgene was performed
with the aid of a Quick Ligation Kit (New England Biolabs).
Production of Infectious Lentiviral Particles
Infectious lentiviral particles containing LVUTPLA2G2Awere produced as
previously described.9 Briefly, HEK293 T cells were plated in 60-mmn in esophageal adenocarcinoma cell lines. A, Immunofluorescence micros-
al adenocarcinoma cell lines FLO-1 and OE33. Nuclei are stained blue, and
tion shows near equal expression of group IIa secretory phospholipase A2 in
mRNA, messenger RNA; NS, not statistically significant.
rdiovascular Surgery c Volume 139, Number 3 593
FIGURE 2. Effect of group IIa secretory phospholipase A2 inhibition
on esophageal adenocarcinoma cell number. Relative cell numbers after
72 hours of treatment of FLO-1 cells (A) and OE33 cells (B) relative to con-
trols, as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide assay. Statistical significance relative to untreated controls
and vehicle (dimethyl sulfoxide, DMSO) controls was reached with 10-
and 20-mmol/L doses for FLO-1 cells and with 5-, 10-, and 20-mmol/L doses
for OE33 cells.
FIGURE 3. Effect of group IIa secretory phospholipase A2 inhibition on
esophageal adenocarcinoma cellular proliferation. Relative bromodeoxyur-
idine (BrdU) incorporation after 72 hours of treatment in FLO-1 cells (A)
and OE33 cells (B) relative to controls. Statistical significance versus
both untreated and vehicle (dimethyl sulfoxide, DMSO) controls was
reached with 10- and 20-mmol/L doses in both cell types.
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transfected with the LVUTPLA2G2A construct, a packaging vector (pPAX2;
Addgene, Cambridge, Mass), and an envelope vector (pMD2; Addgene)
with Effectene transfection reagent (Qiagen). At approximately 24 hours af-
ter transfection, the cell culture medium was replaced with viral collection
medium and incubated for a further 30 hours. This medium was then col-
lected and filtered through a 0.45-mm filter to remove any cellular debris.
Viral stocks were stored at80C until further use.
Overexpression of PLA2G2A
FLO-1 and OE33 cells were cultured in 6-well plates at a density of
3 3 105 cells per well. After 48 hours, growth medium was removed
and replaced with fresh growth medium containing 0.25 mL filtered
LVUTPLA2G2A infectious viral particles. This volume was based on
GFP expression in FLO-1 and OE33 cells from titration experiments
with LVUT viral stocks. Approximately 24 hours after infection, me-
dium containing viral particles was removed and replaced with fresh
growth medium. Overexpression of group IIa sPLA2 protein was as-
sessed with immunofluorescence microscopy as described previously.
Lentiviral Knockdown of PLA2G2A
Four short hairpin RNA (shRNA) constructs for PLA2G2A as well as
a nontargeting shRNA construct in a pLKO.1 puro lentiviral vector were
purchased from Sigma. The sense sequences of these constructs are shown
in Table 1. Infectious lentiviral stocks were produced with these constructs
as described previously. Titration experiments were performed with infec-
tious stocks containing a GFP-containing pLKO.1 puro lentivirus. FLO-1
and OE33 cells were cultured in 6-well plates at a density of 3 3 105594 The Journal of Thoracic and Cardiovascular Surgcells/well and infected with growth medium containing 0.5 mL filtered viral
stock of each PLA2G2A construct. After 24 hours of infection, medium con-
taining viral particles was removed and replaced with fresh growth medium.
Knockdown of PLA2G2A expression was determined with quantitative RT-
PCR, and knockdown of protein expression was assessed with immunoflu-
orescence microscopy.
Quantitation of Viable Cell Number and Cellular
Proliferation of Cells Infected With Lentivirus
Cells infected with lentiviral vectors were subcultured in 96-well plates
at a density of 1 3 104 cells/well in growth medium for 48 hours, at which
point the medium was replaced with serum-reduced medium. Cells were
grown in serum-reduced medium for 72 hours before assessment of viable
cell number and cellular proliferation with MTT or BrdU assays, respec-
tively. All experiments with infected cells included 3 wells of untransfected
control cells. Cells infected with LVUTPLA2G2A were also compared with
cells transfected with LVUTGFP as a transfection control. Cells infected
with PLA2G2A shRNA lentiviral constructs were compared with cells in-
fected with a nontargeting shRNA construct as a transfection control.
Statistical Analysis
Cell viability and proliferation studies were performed in triplicate wells.
The mean of all observations from a single experiment was compared with
that of control cells on the same tissue culture plate and regarded as n ¼ 1.
Each experiment was repeated 3 times. LDH cytotoxicity studies were per-
formed in duplicate wells, and the treatment groups were compared with
both the control group and blank. Statistics were performed with analysis
of variance with a Fisher post hoc analysis.ery c March 2010
FIGURE 4. Infection of esophageal adenocarcinoma cells with lentiviral particles. Both FLO-1 and OE33 cells are efficiently infected with lentiviral par-
ticles derived from lentiviral expression vector pLVUT-tTR-KRAB (LVUT) and pLKO.1 puro constructs, as shown by green fluorescent protein expression
under ultraviolet (UV) light (green). Infection with lentiviral particles did not affect cell shape or size.
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Expression of Group IIa sPLA2 in Esophageal
Cancer Cells
Immunofluorescence microscopy demonstrated that both
OE33 and FLO-1 cells showed expression of sPLA2 protein
within the cytoplasm (Figure 1, A). Further, we confirmed
that the cellular levels of sPLA2 messenger RNA expression
were similar between the 2 cancer cell lines according to
RT-PCR. Representative PCR product bands from ethid-
ium-stained gels as well as band densitometry are shown
in Figure 1 (B and C). The sPLA2 primers were verified
with a plasmid containing the coding sequence for the
PLA2G2A gene.Inhibition of sPLA2 Reduces Viable Cell Number and
Cell Proliferation in OE33 and FLO-1 Cells
Treatment of both OE33 and FLO-1 esophageal adeno-
carcinoma cells with the sPLA2 inhibitor produced a dose-
dependent decrease in viable cell number across the dose
range of 1 to 20 mmol/L. The 10- and 20-mmol/L doses pro-
duced 11% and 50% reductions in viable cell number, re-
spectively, in FLO-1 cells (Figure 2, A). OE33 cells were
more sensitive to sPLA2 inhibition, showing 7%, 31%, and
69% reductions in viable cell number with 5-, 10-, and
20-mmol/L doses, respectively (Figure 2, B).
To examine whether the reduced viable cell number mea-
sured by the MTT assay reflected decreased proliferation,
we quantified cellular proliferation with a BrdU incorpora-
tion assay. FLO-1 cells showed 20% and 70% decreases
in proliferation relative to control with 10-mmol/L and 20-The Journal of Thoracic and Cammol/L doses of sPLA2 inhibitor, respectively (Figure 3,
A). Similarly, OE33 cells demonstrated 30% and 65%
reductions in proliferation with 10- and 20-mmol/L doses,
respectively (Figure 3, B). The sPLA2 inhibitor did not cause
any cell necrosis at any of the doses used in this study, as
determined by LDH activity assay (data not shown).
Overexpression of Group IIa sPLA2 Results in
Augmented Growth of Esophageal Adenocarcinoma
Cells
Both FLO-1 and OE33 cells were efficiently infected with
LVUT lentiviral particles without effect on the health of the
cells (Figure 4, A). FLO-1 and OE33 cells infected with the
LVUTPLA2G2A particles showed 20-fold and 16-fold
increases in expression of the enzyme, as shown by quanti-
tative RT-PCR (Figure 5, A). Immunofluorescent staining
showed increased group IIa sPLA2 expression in cells in-
fected with LVUTPLA2G2A particles (Figure 5, B). Overex-
pression of group IIa sPLA2 in FLO-1 cells led to an 18%
increase in number of viable cells and a 25% increase in
cell proliferation. This effect was similar in OE33 cells,
with a 16% increase in viable cell number and a 17%
increase in cell proliferation (Figure 5, C and D).
Gene Knockdown of PLA2G2A Results in Attenuated
Growth of Esophageal Adenocarcinoma Cells
Both FLO-1 and OE33 cells were efficiently infected with
pLKO.1 puro lentiviral particles without affecting cell health
(Figure 4, B). Infection with PLA2G2A shRNA viral parti-
cles led to 80% and 75% reductions in enzyme expressionrdiovascular Surgery c Volume 139, Number 3 595
FIGURE 5. Overexpression of group IIa secretory phospholipase A2 (sPLA2) in esophageal adenocarcinoma cells augments cell growth. A, In quantitative
reverse transcriptase polymerase chain reaction analysis of FLO-1 and OE33 cells infected with lentiviral expression vector pLVUT-tTR-KRAB (LVUT)with
gene for secretory phospholipase A2, viral particles show significant overexpression of group IIa secretory phospholipase A2 relative to controls. B, Immu-
nofluorescent microscopy of both FLO-1 and OE33 cells shows increased protein levels of group IIa secretory phospholipase A2 (red) in cytoplasm of cells
infected with viral particles derived from pLVUT-tTR-KRAB–secretory phospholipase A2 gene construct. C, Viable cell number is increased in both FLO-1
and OE33 cells that overexpress group IIa secretory phospholipase A2 relative to uninfected and pLVUT-tTR-KRAB–infected controls. D, FLO-1 and OE33
cells that overexpress group IIa secretory phospholipase A2 demonstrate greater cell proliferation than controls. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; UT, untreated; BrdU, bromodeoxyuridine.
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tative RT-PCR (Figure 6, A). Immunofluorescent staining
showed decreased group IIa sPLA2 protein levels in cells in-596 The Journal of Thoracic and Cardiovascular Surgfected with pLKO.1 puro PLA2G2A shRNA particles (Fig-
ure 6, B), indicating effective knockdown of the gene.
Knockdown of PLA2G2A expression in FLO-1 cellsery c March 2010
FIGURE 6. Genetic knockdown of group IIa secretory phospholipase A2 (sPLA2) attenuates growth of esophageal adenocarcinoma cells. A, Quantitative
reverse transcriptase polymerase chain reaction analysis of FLO-1 and OE33 cells infected with group IIa secretory phospholipase A2 short hairpin RNA
(shRNA) viral particles shows significant reduction in expression relative to nontargeting (NT) and untreated (UT) controls. B, Immunofluorescent microscopy
of both FLO-1 and OE33 cells shows decreased protein levels of group IIa secretory phospholipase A2 (red) in cells infected with secretory phospholipase A2
short hairpin RNA viral particles relative to nontargeting short hairpin RNA control. C, Viable cell number is diminished in both FLO-1 and OE33 cells that
have genetic knockdown of group IIa secretory phospholipase A2 transcript relative to uninfected and nontargeting controls. D, Knockdown of group IIa
secretory phospholipase A2 expression results in attenuated cell proliferation relative to uninfected and nontargeting short hairpin RNA controls. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; BrdU, bromodeoxyuridine.
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liferation. OE33 cells showed similar reductions in both cell
number and proliferation after knockdown of PLA2G2A ex-
pression (Figure 6, C and D).The Journal of Thoracic and CaDISCUSSION
Overexpression of sPLA2 protein has been found in sev-
eral types of malignancy, including breast, ovarian, prostate,
and pancreatic cancers10; however, the role of this enzyme inrdiovascular Surgery c Volume 139, Number 3 597
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sPLA2 protein is expressed in the esophageal adenocarci-
noma cell lines OE33 and FLO-1. With lentiviral infection
techniques, we were able to create separate cell lines of
both OE33 and FLO-1 cells that either stably overexpressed
or minimally expressed the group IIa sPLA2 enzyme. For the
first time, we have illustrated the important role of this pro-
tein in growth regulation of esophageal adenocarcinoma
cells by demonstrating that pharmacologic inhibition or ge-
netic knockdown of this enzyme results in decreases in both
viable cell number and cellular proliferation in esophageal
adenocarcinoma cells. Furthermore, overexpression of this
protein leads to augmented cell growth, as indicated by via-
ble cell number and proliferation.
Our results accordwith those of an earlier study that looked
at the effect of overexpression of sPLA2 on colon tumor
cells.11 In that study, the authors transfected colon tumor cells
with PLA2G2A and found that cells overexpressing the en-
zyme developed into larger,more invasive tumors than vector
controls when injected into nudemice.11 In contradistinction,
the homologous murine Pla2g2a gene has been shown to
confer resistance to intestinal tumorigenesis.12,13 Addition-
ally, elevated expression of the enzyme inhibits gastric cancer
invasion and metastasis.14 The discrepancy between these
studies likely has to do with differences in tumor histology
and level of enzyme expression. Group IIa sPLA2 has both
inflammatory and anti-inflammatory properties, which could
also contribute to these differences.7
Overexpression of group IIa sPLA2 is often accompanied
by an increase in production of COX-2, an enzyme that cat-
alyzes the synthesis of bioactive prostaglandins from arach-
idonic acid.15,16 COX-2 has been implicated in the
development and progression of cancers of the gastrointesti-
nal tract, including colorectal, gastric, and esophageal ade-
nocarcinomas.17 Prostaglandin E2 (PGE2), a downstream
product of COX-2, is the most important COX-2–derived
prostaglandin involved in oncogenesis. It has been shown
to play roles in tumor cell proliferation, invasion, angiogen-
esis, and immunosuppression.18 Several cell culture studies
have illustrated the roles of COX-2 and PGE2 in cellular pro-
liferation in esophageal cancer.19-21 One study showed that
cultured esophageal squamous cell cancer cells expressed
high levels of the PGE2 receptor EP2. Those authors were
also able to show significant reduction in cellular prolifera-
tion with pharmacologic blockade or RNA knockdown of
the EP2 receptor.
20 Other authors have used OE33 cells to
show that treatment with an agonist of the EP2 receptor is
able to prevent apoptosis and enhance cellular migration.19
It would be reasonable to speculate that the finding of
decreased cellular proliferation after treatment with an inhib-
itor of group IIa sPLA2 could be directly related to decreased
production of PGE2.
Arachidonic acid liberated by group IIa sPLA2 can also
be converted to mitogenic leukotrienes by 5-lipoxygenase598 The Journal of Thoracic and Cardiovascular Surg(5-LOX). 5-LOX has been shown to be important in the
development of esophageal adenocarcinoma in vivo. The
expression of 5-LOX was increased in esophageal tumors
in both human samples and samples from rats that had
been exposed to surgically induced mixed reflux. Further-
more, incidence of tumor development was decreased by
36% in animals with reflux treated with zileuton, a specific
inhibitor of 5-LOX.22 Another group showed that several
esophageal cancer cell lines express 5-LOX and that inhibi-
tion of this enzyme leads to decreased production of leuko-
triene B4 and increased rates of apoptosis.
23 It is possible that
some of the decrease in viable cell number seen with inhibi-
tion of group IIa sPLA2 in our study is related to decreased
leukotriene B4 production and increased apoptosis.
Group IIa sPLA2 has also been shown tomodulate cellular
proliferation in arachidonic acid–independent mechanisms.
Xie and colleagues24 found that inhibition of hepatocellular
carcinoma cells with the sPLA2 inhibitor 12-epi-scalaradial
blocked epidermal growth factor receptor–regulated activa-
tion of Akt, the phosphorylation of which can lead to in-
creased cellular proliferation or decreased apoptosis.24 This
was found to act in an arachidonic acid–independent fashion.
The authors of that paper also found scalaradial to inhibit
phosphorylation of the mitogen-activated protein kinase ex-
tracellular signal-regulated kinase 1/2,which has been shown
to regulate cellular proliferation in several cell types.25
The observations in this study suggest that group IIa
sPLA2 is an important contributor to cellular proliferation
in esophageal adenocarcinoma cells. To our knowledge,
this is the first report of pharmacologic inhibition and genetic
knockdown of group IIa sPLA2 attenuating proliferation in
esophageal adenocarcinoma cells. Further animal studies
are needed to assess the importance of this enzyme in
vivo; however, group IIa sPLA2 remains a potential target
for treatment of malignancy.References
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Dr RossM. Bremner (Phoenix, Ariz). I thank DrMauchley and
colleagues for providing me with a manuscript well in advance of
the meeting, but even more for providing me with a new and im-
proved manuscript just this morning. This manuscript contains all
their latest data, and it is a tribute to the Society that the opportunity
of presenting this work today has stimulated Dr Mauchley and col-
leagues to produce another set of fairly intricate experiments to
greatly add to this article. In fact, the manuscript is quite impressive.
The group has previously, as we were reminded this morning,
taught us that this enzyme, sPLA2, is important in reflux disease.
This morning they have answered a question regarding whether
this enzyme is also important in mature adenocarcinoma cells.
The study was clearly planned and expertly performed, but I do
have a few questions. The first question regards the specificity ofThe Journal of Thoracic and Cathe inhibitor. Dr Mauchley, how have you convinced yourselves
that the inhibitor is working at the doses you used by looking at
downstream indicators such as LOX or COX activity or leukotriene
or prostaglandin production?
Dr Mauchley. First, I thank you for your comments. To answer
your first question, this inhibitor was developed by a group in
Australia. According to 2 of their initial publications, they deter-
mined that it was a group IIA–specific inhibitor by testing it against
human recombinant group IIA sPLA2 as well as a few of the other
isoforms.
With respect to looking at downstream players in the whole
sPLA2 signal transduction pathway, we have not done that yet, al-
though we plan to do so. In particular, I think that it is important to
look at PGE2 and leukotriene B4 production. We have collaborated
with a lipid group at the university that does mass spectrometry to
help us look into this.
Dr Bremner. I think that will be important. The studies showed
that the inhibition of sPLA2 decreased the number of viable cells in
your cultures. Do you think that this is really a proapoptotic effect,
or do you think that this is cell cycle arrest?
DrMauchley. That is a good question. So far, most of our work
in this area has been to assess proliferation; however, we do have
some early preliminary results with the FLO-1 cells that indicate
that this is more a proliferative process and less of an apoptotic pro-
cess. We used flow cytometry to try to stain for apoptotic cells
treated in a similar fashion and found very little difference.
Dr Bremner. This latest set of experiments that you did trans-
fecting cells with sPLA2 and then having a group of experiments
with knockdown of sPLA2 was very interesting. In your knock-
down group, though, I was surprised that you showed only a modest
reduction in cell proliferation, about 15%. Did you consider this
disappointing? Because it seems that blocking sPLA2 is not really
essential for cell proliferation, have you considered adding a se-
quential downstream inhibitor, such as a LOX or COX-2 inhibitor,
to see what the effect would be?
DrMauchley. First, I was not discouraged at all by the findings.
Although we showed efficient transfection with the GFP-contain-
ing construct, it was impossible to know whether transfection
was as efficient with the PLA2G2A construct. This could explain
the modesty of the reduction.
With respect to using other inhibitors, we have talked about that
in the past. We have experiments planned but have not conducted
any at this point.
DrBremner. Finally, your studies really sidestep the question of
how this inhibitor would work in an animal system. Is this inhibitor
toxic at all, and do you plan animal experiments to see how it works
on a tumor model in a mouse, for example?
Dr Mauchley. Yes, we are in the process of getting a protocol
amendment approved so that we can inject these cells into nude
mice subcutaneously and assess their growth. The inhibitor that
we use is actually orally bioavailable, and in some of our previous
work we were able to get significant inhibition in vivo by gavage-
feeding mice with the inhibitor. We are planning on feeding the in-
hibitor to mice to see whether we can attenuate growth in vivo as
well as to use the transfected cell lines to see whether we can get
increased growth with overexpression.
Dr Bremner. Fascinating work. Thank you very much.rdiovascular Surgery c Volume 139, Number 3 599
